Last reviewed · How we verify
BD MDI 160 µg
BD MDI 160 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD.
BD MDI 160 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD. Used for Maintenance treatment of asthma, Maintenance treatment of COPD.
At a glance
| Generic name | BD MDI 160 µg |
|---|---|
| Also known as | PT008 |
| Sponsor | Pearl Therapeutics, Inc. |
| Drug class | Corticosteroid inhaler |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
BD MDI 160 µg contains a medication called fluticasone propionate, which is a corticosteroid that reduces inflammation in the airways. This helps to prevent symptoms of asthma and COPD, such as wheezing and shortness of breath.
Approved indications
- Maintenance treatment of asthma
- Maintenance treatment of COPD
Common side effects
- Oral thrush
- Headache
- Cough
- Sore throat
- Hoarseness
Key clinical trials
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (PHASE3)
- Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |